看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | 56.2x - 62.1x | 59.1x |
| Selected Fwd P/E Multiple | 23.0x - 25.5x | 24.2x |
| Fair Value | $72.85 - $80.51 | $76.68 |
| Upside | -28.0% - -20.5% | -24.3% |
| Benchmarks | - | Full Ticker |
| Delcath Systems, Inc. | - | NasdaqCM:DCTH |
| Nevro Corp. | - | NYSE:NVRO |
| AtriCure, Inc. | - | NasdaqGM:ATRC |
| Avanos Medical, Inc. | - | NYSE:AVNS |
| Bioventus Inc. | - | NasdaqGS:BVS |
| Boston Scientific Corporation | - | NYSE:BSX |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| DCTH | NVRO | ATRC | AVNS | BVS | BSX | |||
| NasdaqCM:DCTH | NYSE:NVRO | NasdaqGM:ATRC | NYSE:AVNS | NasdaqGS:BVS | NYSE:BSX | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | -17.0% | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | 23.4% | ||
| Latest Twelve Months | 44.7% | -23.0% | -46.8% | -3802.0% | 65.3% | 18.0% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -998.2% | -19.9% | -8.2% | -4.1% | -14.2% | 12.3% | ||
| Prior Fiscal Year | -2308.9% | -21.7% | -7.6% | -1.5% | -18.9% | 11.0% | ||
| Latest Fiscal Year | -70.9% | -27.8% | -9.6% | -56.2% | -5.9% | 11.1% | ||
| Latest Twelve Months | -70.9% | -27.8% | -9.6% | -56.2% | -5.9% | 11.1% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | -30.0x | -2.1x | -74.5x | 8.0x | 16.5x | 37.6x | ||
| Price / LTM Sales | 11.3x | 0.5x | 3.5x | 1.0x | 1.1x | 8.9x | ||
| LTM P/E Ratio | -15.9x | -2.0x | -36.5x | -1.7x | -18.5x | 80.8x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -36.5x | -15.9x | -1.7x | |||||
| Historical LTM P/E Ratio | 14.0x | 71.1x | 111.2x | |||||
| Selected P/E Multiple | 56.2x | 59.1x | 62.1x | |||||
| (x) LTM Net Income | 1,853 | 1,853 | 1,853 | |||||
| (=) Equity Value | 104,052 | 109,528 | 115,005 | |||||
| (/) Shares Outstanding | 1,479.1 | 1,479.1 | 1,479.1 | |||||
| Implied Value Range | 70.35 | 74.05 | 77.75 | |||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 70.35 | 74.05 | 77.75 | 101.24 | ||||
| Upside / (Downside) | -30.5% | -26.9% | -23.2% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | DCTH | NVRO | ATRC | AVNS | BVS | BSX | |
| Value of Common Equity | 420 | 221 | 1,631 | 660 | 620 | 149,741 | |
| (/) Shares Outstanding | 33.4 | 37.9 | 48.9 | 46.0 | 66.2 | 1,479.1 | |
| Implied Stock Price | 12.57 | 5.84 | 33.36 | 14.35 | 9.37 | 101.24 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 12.57 | 5.84 | 33.36 | 14.35 | 9.37 | 101.24 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |